Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03850379 · ClinicalTrials.gov registry record · Phase 2
Ciprofloxacin Versus Levofloxacin in Stem Cell Transplant
A Phase 2 study of Stem Cell Transplant Complications and Prophylaxis, sponsored by Henry Ford Health System.
- Completed
- Registry status
- Phase 2
- Development phase
- 308
- Enrollment target
- 1
- Study location
NCT03850379: Completed Phase 2 study of Stem Cell Transplant Complications and Prophylaxis, sponsored by Henry Ford Health System.
NCT03850379 is a Phase 2 study of Stem Cell Transplant Complications and Prophylaxis that has completed, run by Henry Ford Health System. The registered enrollment target is 308 participants, above the 165-participant average among 15 other Stem Cell Transplant Complications trials with a reported enrollment target (87% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03850379, a Phase 2 study of Stem Cell Transplant Complications and Prophylaxis, has completed, sponsored by Henry Ford Health System.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 308 participants
- Enrollment target
- 1
- Study location
Study Summary
Ciprofloxacin and levofloxacin are both in guidelines to use for prophylaxis in autologous and allogeneic Stem cell transplant.Ciprofloxacin was recently replaced by levofloxacin as the preferred agent in some transplant centers. In some small retrospective studies ciprofloxacin prophylaxis was associated with a higher rate of breakthrough gram positive bloodstream infections. However, the optimum oral agent for antibacterial prophylaxis in transplant recipients remains uncertain.
Primary Outcome
to assess proportion of bloodstream bacterial infections in the ciprofloxacin group compared to levofloxacin group up to day 60 after stem cell transplant
Conditions Studied
Interventions
- DRUG Ciprofloxacin
- DRUG Levofloxacin
Study Locations (1)
Michigan
- Henry Ford - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 308 participants |
| Start Date | 2018-03-14 |
| Est. Completion | 2024-08-30 |
| Phase | Phase 2 |
What the finished NCT03850379 record still lists
NCT03850379 is an interventional study that assigns participants to a tested intervention. The registered 308 participants enrollment target is mid-sized for trials with a published cap, above the 165-participant average among 15 other Stem Cell Transplant Complications trials with a reported enrollment target (87% higher).
The record links to 2 conditions, with Stem Cell Transplant Complications appearing as the primary indexed condition, and to 2 interventions - of which Ciprofloxacin is the first listed.
NCT03850379 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT03850379 about?
NCT03850379 is a clinical study titled "Ciprofloxacin Versus Levofloxacin in Stem Cell Transplant". Ciprofloxacin and levofloxacin are both in guidelines to use for prophylaxis in autologous and allogeneic Stem cell transplant.Ciprofloxacin was recently replaced by levofloxacin as the preferred agent in some transplant centers. In some small retrospective studies ciprofloxacin prophylaxis was asso...
What is the current status of trial NCT03850379?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 308 participants. The study started on 2018-03-14. Estimated completion is 2024-08-30.
What conditions does trial NCT03850379 study?
This clinical trial studies the following conditions: Stem Cell Transplant Complications, Prophylaxis.
What interventions are being tested in trial NCT03850379?
The interventions under investigation include: Ciprofloxacin (DRUG), Levofloxacin (DRUG).
Who is sponsoring clinical trial NCT03850379?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03850379 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stem Cell Transplant Complications
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03850379's enrollment target sits among peer trials
308 2nd of 15 the highest of 15 other Stem Cell Transplant Complications trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stem Cell Transplant Complications trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases
RECRUITING · Phase 2
-
A Double-blind Randomized Placebo Controlled Clinical Trial Evaluating Effect of Chlorhexidine Gluconate 2% Cloth vs Placebo Cloth Baths on the Incidence of Central Line-Associated Blood Stream Infections in Outpatient Hematopoietic Stem Cell Transplant Patients
COMPLETED · Phase 2
-
A Novel Digital Application (SHIFT) to Improve Outcomes for Hematopoietic Stem Cell Transplant Survivors
RECRUITING · NA
-
Prehabilitation Exercise Training in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
RECRUITING · NA
-
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
RECRUITING · Phase 3
-
Intestinal Microbiota in Stem Cell Transplant Transplant Admission
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04162938 · 308 participants · NA
Use of a Patient-Centered Electronic App to Increase ED Patient's Knowledge on HCV to Improve the HCV Care Continuum
- NCT04955795 · 308 participants · NA
Telemedicine for Unhealthy Alcohol Use in Persons Living With HIV Using CETA
- NCT06090539 · 308 participants · Phase 1
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
- NCT06233942 · 308 participants · Phase 1
Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI